Clinical Trial Update: Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML

View source ↗

Summary

Feasibility study evaluating intermediate-dose cytarabine (Ara-C) with autologous stem cell transplant as consolidation for low- to intermediate-risk acute myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)

Snippet

Sponsor: International Consortium on Acute Leukemias | Conditions: Acute Myeloid Leukemia | Status: UNKNOWN